Xencor (NASDAQ:XNCR) will collaborate with The University of Texas MD Anderson Cancer Center to investigate treatments for a range of cancers leveraging the company’s line-up of XmAb drug candidates, including novel bispecific antibodies and engineered cytokines.
The company will fund and support clinical studies over an initial five-year term.
https://seekingalpha.com/news/3611417-xencor-teams-up-md-anderson-on-xmab-cancer-treatments
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.